📊 DMAC Key Takeaways
Is DiaMedica Therapeutics Inc. (DMAC) a Good Investment?
DiaMedica is a pre-revenue biopharmaceutical company with severe cash burn (-$21.3M operating cash flow) and minimal revenue ($500K), indicating the company is in early clinical stages with substantial development risk. With only $3.3M in cash and annual burn rates exceeding $25M, the company faces critical runway constraints and high dilution risk from future financing.
DiaMedica Therapeutics shows very weak fundamentals, with only $500K of revenue against a $24.03M net loss and deeply negative operating cash flow of $21.30M. While the balance sheet appears lightly levered and current liquidity ratios are high, the absolute cash balance of $3.33M looks thin relative to its cash burn, making funding risk the central issue. Until revenue quality improves materially or cash resources are replenished, the business profile remains highly speculative.
Why Buy DiaMedica Therapeutics Inc. Stock? DMAC Key Strengths
- Strong balance sheet liquidity with 10.67x current ratio and minimal debt
- Positive stockholders equity of $51.6M providing asset backing
- Limited leverage risk with debt-to-equity ratio of 0.00x
- No meaningful leverage, with debt-to-equity at 0.00x
- Strong reported near-term liquidity ratios, with current and quick ratios at 10.67x
- Equity base remains solid at $51.62M, supporting balance-sheet flexibility
DMAC Stock Risks: DiaMedica Therapeutics Inc. Investment Risks
- Severe ongoing cash burn of $21.3M annually with only $3.3M cash on hand - approximately 1-2 months of runway
- Pre-commercial stage with only $500K revenue and negative operating margin of -5037%, indicating no path to profitability in near term
- Extreme free cash flow burn of -$21.3M with FCF margin of -4266%, requiring immediate capital raises and significant dilution risk
- High execution risk typical of biopharmaceutical firms with clinical development timelines uncertain and regulatory approval not guaranteed
- Extremely weak profitability, with operating margin of -5036.8% and net margin of -4805.2%
- Very low revenue base relative to expenses suggests limited commercial traction or pre-scale operations
- Cash burn is severe versus cash on hand, raising near-term financing and dilution risk
Key Metrics to Watch
- Cash position and runway remaining relative to quarterly burn rate
- Clinical trial progress and regulatory milestones for pipeline programs
- Revenue growth trajectory and path to commercialization
- Quarterly operating cash burn versus cash and equivalents
- Revenue growth and progress toward narrowing operating losses
DiaMedica Therapeutics Inc. (DMAC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.67x current ratio provides a solid financial cushion.
DMAC Profit Margin, ROE & Profitability Analysis
DMAC vs Healthcare Sector: How DiaMedica Therapeutics Inc. Compares
How DiaMedica Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DiaMedica Therapeutics Inc. Stock Overvalued? DMAC Valuation Analysis 2026
Based on fundamental analysis, DiaMedica Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DiaMedica Therapeutics Inc. Balance Sheet: DMAC Debt, Cash & Liquidity
DMAC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: DiaMedica Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.60 indicates the company is currently unprofitable.
DMAC Revenue Growth, EPS Growth & YoY Performance
DMAC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2019 | $500.0K | -$1.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DiaMedica Therapeutics Inc. Dividends, Buybacks & Capital Allocation
DMAC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for DiaMedica Therapeutics Inc. (CIK: 0001401040)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DMAC
What is the AI rating for DMAC?
DiaMedica Therapeutics Inc. (DMAC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DMAC's key strengths?
Claude: Strong balance sheet liquidity with 10.67x current ratio and minimal debt. Positive stockholders equity of $51.6M providing asset backing. ChatGPT: No meaningful leverage, with debt-to-equity at 0.00x. Strong reported near-term liquidity ratios, with current and quick ratios at 10.67x.
What are the risks of investing in DMAC?
Claude: Severe ongoing cash burn of $21.3M annually with only $3.3M cash on hand - approximately 1-2 months of runway. Pre-commercial stage with only $500K revenue and negative operating margin of -5037%, indicating no path to profitability in near term. ChatGPT: Extremely weak profitability, with operating margin of -5036.8% and net margin of -4805.2%. Very low revenue base relative to expenses suggests limited commercial traction or pre-scale operations.
What is DMAC's revenue and growth?
DiaMedica Therapeutics Inc. reported revenue of $500.0K.
Does DMAC pay dividends?
DiaMedica Therapeutics Inc. does not currently pay dividends.
Where can I find DMAC SEC filings?
Official SEC filings for DiaMedica Therapeutics Inc. (CIK: 0001401040) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DMAC's EPS?
DiaMedica Therapeutics Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DMAC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, DiaMedica Therapeutics Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DMAC stock overvalued or undervalued?
Valuation metrics for DMAC: ROE of -46.5% (sector avg: 15%), net margin of -4,805.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DMAC stock in 2026?
Our dual AI analysis gives DiaMedica Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DMAC's free cash flow?
DiaMedica Therapeutics Inc.'s operating cash flow is $-21.3M, with capital expenditures of $34.0K. FCF margin is -4,266.2%.
How does DMAC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,805.2% (avg: 12%), ROE -46.5% (avg: 15%), current ratio 10.67 (avg: 2).